.................................................... รายการ ปี 25XX อัตราส่วนสภาพคล่อง (current ratio) (เท่า) ความสามารถในการชำระดอกเบี้ย (interest coverage ratio : ICR) (เท่า) หนี้สินที่มีภาระดอกเบี้ยต่อกำไรก่อนดอกเบี้ยจ่าย ภาษีเงินได้ ค่าเสื่อมราคาและค่า

1 No. ACE-ACC-2/2023 12 May 2023 Subject Management Discussion and Analysis for the period ended 31 March 2023 To President The Stock Exchange of Thailand Absolute Clean Energy Public Company Limited

in Q1 2024. The gain on foreign currency exchange in Q1 2024 was mainly associated with other current financial assets in USD related to the proceeds from sale of Sakthi auto component Limited (SACL

Exchange of Thailand Absolute Clean Energy Public Company Limited (“the Company”), are pleased to provide you our management discussion and analysis for the period ended 31 March 2024 of the Company and the

(current ratio) (เท่า) ความสามารถในการชำระดอกเบี้ย (interest coverage ratio : ICR) (เท่า) หนี้สินที่มีภาระดอกเบี้ยต่อกำไรก่อนดอกเบี้ยจ่าย ภาษีเงินได้ ค่าเสื่อมราคาและ ค่าตัดจำหน่าย (interest bearing debt to

Systems for the MRT Blue Line Extension Project, to ensure the efficient train operation service and in accordance with the conditions of the Concession Agreement. The Company intends to engage CH

for the launch of the production automation under the scheme of “Delta Smart Manufacturing”. The company believes that it would benefit the company by enhancing energy saving and improving the

.06%, mainly due to decreasing of current investment in amount of Baht 15 .00 million (because it reached the maturity term and became 3-months deposit so it was classified as cash and cash equivalent

development improvement and equipment, cash and equivalents. More total liabilities which increase at amount Baht 26.85 million or 3.74%, as defaulted liabilities, Trade and other current payable, finance lease

32.6 Debt Service Coverage 904.1 4.4 103.9 4.6 Total Debt to Equity 0.2 0.4 0.2 0.4 * calculated by using earnings of current quarter to be estimated for annual earnings ** based on only cost of medicine